ReviewClinical and translational allergy2020
Highlights and recent developments in allergic diseases in EAACI journals (2019).
Review in Clinical and translational allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Pooled it
- Antidiabetic Properties of Histamine H1 Receptor Antagonists: A Systematic Review.Antioxidants (Basel, Switzerland) · 2026Review
- Developments in the Management Strategies for Allergy: Advances in Artificial Intelligence and Future Perspectives.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026Review
- Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Research advances on epigenetic modifications in dendritic cells in allergic rhinitis.Frontiers in immunology · 2025Review
- Livin promotes Th2-type immune response in airway allergic diseases.Immunologic research · 2022Article
- Detecting common allergens in dogs with atopic dermatitis in South Korean Provinces using a serological immunoglobulin E-specific allergen test.Veterinary world · 2022Article
- Enhanced expression of endogenous retroviruses and of TRIM28 and SETDB1 in children with food allergy.Clinical and translational allergy · 2022Article
- Review
- Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. There was substantial progress in 2019 in the identification of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better understanding of molecular and cellular mechanisms, efforts for the development of biomarkers for disease prediction, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, entrance of new drugs in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen immunotherapy studies and meta-analyses have been the highlights of the last year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.